Immune Checkpoint Inhibitors: all 7,814 studies that test it
Page 67 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.
- Phase 1, First in Human, Open-Label, Dose-Escalation Study of 609AStatus unknownNCT03950297Phase 1
- Cryotherapy With in Situ Immunotherapy in Melanoma MetastasisCompletedNCT03949153Phase 1/2
- Sintilimab in Combination With Chemotherapy in Neoadjuvant Treatment of Potentially Resectable Esophageal CancerStatus unknownNCT03946969Phase 2
- Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic SarcomaStatus unknownNCT03946943Phase 2
- JS001 Combined With Regorafenib in Patients With Advanced Colorectal CancerStatus unknownNCT03946917Phase 1/2
- Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)CompletedNCT03946358Phase 2
- A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBCCompletedNCT03945604Phase 1
- Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid TumorsCompletedNCT03945253Phase 1
- Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)Active, not recruitingNCT03944772Phase 2
- Cetuximab + Avelumab or Avelumab Alone for Unresectable, Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (SCCAC) Progressed After at Least One Line of Systemic Treatment (CARACAS)Status unknownNCT03944252Phase 2
- Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland CarcinomaActive, not recruitingNCT03942653Phase 2
- Phase II Study in the Treatment of Patients With Advanced Mucinous MelanomaStatus unknownNCT03941795Phase 2
- HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)TerminatedNCT03940352Phase 1
- A Study of Sintilimab Plus Chemoradiation Before Surgery for Esophageal CancerStatus unknownNCT03940001Early Phase 1
- Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract CancerCompletedNCT03937895Phase 1/2
- Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract CarcinomaActive, not recruitingNCT03937830Phase 2
- Combined Treatment of Sintilimab, Peg-aspargase Plus Anlotinib in NK/T Cell LymphomaCompletedNCT03936452Phase 2
- Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based ChemotherapyWithdrawnNCT03935347Phase 2
- Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial CancerActive, not recruitingNCT03932409Phase 1
- Programmed Death-1 (PD-1) Antibody Combined With Chemoradiotherapy in High-risk Recurrent Nasopharyngeal CarcinomaActive, not recruitingNCT03930498Phase 2
- Phase II Study of Toripalimab Plus Stereotactic Body Radiotherapy in Colorectal Cancer Patients With OligometastasisStatus unknownNCT03927898Phase 2
- KN046 in Patients With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT03927495Phase 2
- PAC-1 for Treatment of Refractory, Metastatic Kidney CancerWithdrawnNCT03927248Phase 1/2
- KN046 in Subjects With Late Stage Esophageal Squamous Cell CarcinomaCompletedNCT03925870Phase 2
- Efficacy of Nivolumab for Recurrent IDH Mutated High-Grade GliomasCompletedNCT03925246Phase 2
- Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC PatientsActive, not recruitingNCT03925090Phase 2
- Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)CompletedNCT03924856Phase 3
- Toripalimab Plus Pemetrexed+Platinus in Advanced Non-small-cell Lungcancer Patients Previsouly Treated EGFR-TKICompletedNCT03924050Phase 3
- Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung CancerActive, not recruitingNCT03923270Phase 1
- A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerCompletedNCT03922997Phase 3
- A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic MalignanciesCompletedNCT03922204Phase 1
- Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer PatientsActive, not recruitingNCT03921684Phase 2
- Phase II of Lenvatinib Plus Toripalimab for Advanced HCCWithdrawnNCT03919383Phase 2
- A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)CompletedNCT03918278Phase 1
- Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural MesotheliomaActive, not recruitingNCT03918252Phase 2
- The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCCStatus unknownNCT03917966Phase 2
- Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult PatientsActive, not recruitingNCT03916627Phase 2
- A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal CarcinomaCompletedNCT03914443Phase 1
- A Novel Immunotherapy PD-1 Antiboty to Suppress Recurrence of HCC Combined With PVTT After Hepatic ResectionStatus unknownNCT03914352Not applicable
- Study of Efficacy and Safety of BCD-217 (Anti-CTLA-4 and Anti-PD-1) Followed By BCD-100 (Anti-PD-1) Versus BCD-100 Monotherapy as First-Line Treatment in Patients With Unresectable or Metastatic MelanomaStatus unknownNCT03913923Phase 2
- Camrelizumab(SHR-1210) Combined With Apatinib in the Treatment of Advanced Metastatic Colorectal CancerStatus unknownNCT03912857Phase 2
- Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy With and Without Bevacizumab as First-Line Treatment of Subjects With Advanced Cervical Cancer (FERMATA)Status unknownNCT03912415Phase 3
- Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy and Bevacizumab in Patients With Recurrent, Persistent or Metastatic Cervical Cancer (CAESURA)Status unknownNCT03912402Phase 2
- Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLCStatus unknownNCT03912389Phase 3
- A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.CompletedNCT03910660Phase 1/2
- A Study of INCMGA00012, INCB001158, and the Combination in Japanese Participants With Advanced Solid TumorsCompletedNCT03910530Phase 1
- Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）Status unknownNCT03910127Phase 1
- A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck CancerTerminatedNCT03906526Phase 1
- CM082 and JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC)Status unknownNCT03904719Phase 2
- Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine CarcinomaWithdrawnNCT03901378Phase 2
- Pembrolizumab for Newly Diagnosed GlioblastomaActive, not recruitingNCT03899857Phase 2
- A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)Status unknownNCT03899610Phase 2
- Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid TumorsStatus unknownNCT03897283Phase 1
- Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)Active, not recruitingNCT03896074Phase 2
- Lenvatinib Combined Pembrolizumab in Advanced Hepatobiliary TumorsCompletedNCT03895970Phase 2
- RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical CancerTerminatedNCT03894215Phase 2
- Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast CancerTerminatedNCT03894007Phase 2
- A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT03893955Phase 1
- AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse GliomaCompletedNCT03893903Phase 1
- Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC)CompletedNCT03893695Phase 1/2
- Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell LymphomaTerminatedNCT03892525Phase 1
- Duvelisib and Nivolumab in Treating Patients With Richter Syndrome or Transformed Follicular LymphomaCompletedNCT03892044Phase 1
- Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic AdenocarcinomaWithdrawnNCT03891979Phase 4
- Avelumab as Single Agent in Metastatic or Locally Advanced Urothelial Cancer in Patients Unfit for Cisplatin. The ARIES StudyCompletedNCT03891238Phase 2
- Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent GlioblastomaCompletedNCT03890952Phase 2
- Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell CarcinomaCompletedNCT03889912Phase 1
- Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin LymphomaActive, not recruitingNCT03884998Phase 1
- First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)-China Extension StudyWithdrawnNCT03881111Phase 3
- Determining the Effects of Temozolomide Followed by Nivolumab in Patients With Colorectal CancerWithdrawnNCT03879811Phase 2
- Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 MutationStatus unknownNCT03879174Phase 2
- A Trial of Immunotherapy Strategies in Metastatic Hormone-sensitive Prostate CancerStatus unknownNCT03879122Phase 2/3
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedNCT03878524Phase 1
- Neoadjuvant Immunotherapy for Resectable Gastric CancerCompletedNCT03878472Phase 2
- Neo-adjuvant Chemotherapy Combined With Stereotactic Body Radiotherapy to the Primary Tumour +/- Durvalumab, +/- Oleclumab in Luminal B Breast Cancer:Active, not recruitingNCT03875573Phase 2
- Study of IBI318 in Participants With Advanced MalignanciesCompletedNCT03875157Phase 1
- Sintilimab Combined With Metformin in First-Line Chemotherapy Refractory Advanced NSCLC PatientsStatus unknownNCT03874000Phase 2
- A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney CancerActive, not recruitingNCT03873402Phase 3
- A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell LymphomaWithdrawnNCT03873025Phase 1/2
- A Study of KN046 in Subjects With Locally Advanced or Metastatic Triple-negative Breast CancerCompletedNCT03872791Phase 1/2
- A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid TumorsTerminatedNCT03871855Phase 1
- Improve Checkpoint-blockade Response in Advanced Urothelial CancerCompletedNCT03871036Phase 1/2
- HAIC Combined with PD-1 Inhibitor in Potentially Resectable Locally Advanced HCCActive, not recruitingNCT03869034Phase 2
- iSCORE: Immunotherapy Sequencing in COlon and REctal CancerActive, not recruitingNCT03867799Phase 2
- Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular CarcinomaTerminatedNCT03867370Phase 1/2
- A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung CancerCompletedNCT03866993Phase 3
- A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung CancerTerminatedNCT03866980Phase 3
- A Study of Anti-PD-1 AK105 in Patients With Metastatic Nasopharyngeal CarcinomaCompletedNCT03866967Phase 2
- A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal AdenocarcinomaTerminatedNCT03866239Phase 1
- Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)Active, not recruitingNCT03865082Phase 2
- A Study of Sintilimab or Placebo in Combination With Chemotherapy as Second-line Treatment for Patients With Stage IV Nonsquamous Non-small Cell Lung Cancer With Wild-type EGFR After Failure With Platinum-Containing Chemotherapy.Status unknownNCT03863483Phase 2
- Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerActive, not recruitingNCT03860272Phase 1
- Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical ResectionActive, not recruitingNCT03859128Phase 2/3
- neoadjuvant_thymic Epithelial TumorStatus unknownNCT03858582Phase 2
- A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLCCompletedNCT03856411Phase 3
- IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma.Status unknownNCT03854838Phase 2
- Immunotherapy In Locally Advanced Rectal CancerCompletedNCT03854799Phase 2
- Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial CarcinomaActive, not recruitingNCT03854474Phase 1/2
- Imaging Tumor-infiltrating T-cells in Non-small Cell Lung CancerCompletedNCT03853187Phase 2
- Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced TumoursStatus unknownNCT03852823Phase 1
- A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody, for Advanced Solid Tumors or With mXELOX/XELOX as First-line Therapy for Advanced Gastric or GEJ AdenocarcinomaCompletedNCT03852251Phase 1/2